Cosentyx is a medication used to treat autoimmune diseases such as psoriasis and psoriatic arthritis. The active ingredient in Cosentyx is secukinumab, which is a monoclonal antibody that targets interleukin-17A, a protein that contributes to inflammation. However, the use of Cosentyx during pregnancy may pose risks to the developing fetus.

According to Drugs.com [3], Cosentyx has been assigned a pregnancy category B by the US FDA, which means that animal studies have not shown any adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women. Therefore, the use of Cosentyx during pregnancy should be avoided unless the potential benefits outweigh the potential risks.

A study published in the National Library of Medicine [2] found that there is limited data on the use of Cosentyx during pregnancy. The study reported that there were no adverse outcomes in the infants of three women who were exposed to Cosentyx during pregnancy. However, the sample size was small, and the study concluded that further research is needed to determine the safety of Cosentyx during pregnancy.

Additionally, Drug Patent Watch [1] reports that Cosentyx may pass into breast milk and could harm a nursing infant. Therefore, it is recommended that women who are breastfeeding should not use Cosentyx.

In conclusion, while there is limited data on the use of Cosentyx during pregnancy, the potential risks to the developing fetus should be carefully considered. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of using Cosentyx with their healthcare provider. It is also recommended that women who are breastfeeding should avoid using Cosentyx.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/
[3] https://www.drugs.com/pregnancy/secukinumab.html